NJ-LARSEN-&-TOUBRO-INFOT
2.11.2022 20:46:36 CET | Business Wire | Press release
Fosfor, the Data Products Unit of Larsen & Toubro Infotech (BSE: 540005, NSE: LTI), today announced that it has been approved as a Snowflake Ready Technology Validation Partner. Achieving this validation confirms Fosfor’s DataOps product, Spectra, and Decision Intelligence product, Lumin, adhere to Snowflake’s best practices around performance, reliability, and security.
Under the Snowflake Ready Technology Validation program, Snowflake audits and validates a company’s native integration with Snowflake based on functional and performance best practices. The audit requires a native connector that has been available for at least six months, as well as a set of joint customers and case studies. With this validation, Fosfor joins a list of prominent product companies that have been approved under this program.
“Efficient access to quality data helps organizations quickly inform strategies and decisions – it is a must-have for our customers," says Tarik Dwiek, Head of Technology Alliances at Snowflake. “Fosfor’s take on monetizing data at speed and scale for enterprises complements Snowflake's commitment to capitalizing on the infinite potential of the Data Cloud and creates a winning proposition for our customers.”
Along with LTI recently being awarded Elite tier partner status and receiving the Delivery Partner of the Year award at the 2022 Snowflake Summit, the Technology Ready designation further reinforces the long-standing partnership between the companies. A growing number of Fosfor customers are realizing the synergistic value created by combining Fosfor’s data and AI capabilities with Snowflake’s Data Cloud.
“The Snowflake-Fosfor partnership is a natural fit in exploding value from Data & AI for enterprises globally and is creating immense value for our joint customers with Fosfor products’ seamless native connectivity to Snowflake. Fosfor products like Spectra are solving major DataOps challenges for enterprises, while Lumin converts data into decision insights with ease for business users,” said Satyakam Mohanty, Chief Product Officer, Fosfor. "We are delighted to be in lockstep with Snowflake to strengthen our valued partnership and in our aligned vision to create limitless business impact for enterprises.”
Snowflake has been a key partner of LTI since 2018, and of the Fosfor product suite since its launch in December of 2021. Click here to learn more about the powerful combination of Fosfor and Snowflake.
About Fosfor
The Fosfor Product Suite is the only end-to-end suite for optimizing all aspects of the data-to-decisions lifecycle. Fosfor helps you make better decisions, ensuring you have the right data in more hands in the fastest time possible. The Fosfor Product Suite comprises of Spectra, a comprehensive DataOps platform; Aspect, a no-code unstructured data processing platform; Optic, a data fabric to facilitate data discovery-to-consumption journeys; Refract, a data science and MLOps platform; and Lumin, a decision intelligence platform. Collectively, the Fosfor suite helps businesses discover the hidden value in their data. The Fosfor Data Products Unit is part of LTI, a global technology consulting and digital solutions company with hundreds of clients and operations in 33 countries. For more information, visit www.fosfor.com.
About LTI:
LTI (NSE: LTI) is a global technology consulting and digital solutions company helping more than 500 clients succeed in a converging world. With operations in 33 countries, we go the extra mile to assist our clients and accelerate their digital transformation journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivalled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 50,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees, and shareholders. Learn more at http://www.lntinfotech.com or follow us at @LTI_Global.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102005946/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom